About Venous Thromboembolism Therapeutic
The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.
Technavio’s analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi
Other prominent vendors
• Altor Bioscience
• Armetheon
• Aspen Pharma
• BioInvent International
• eXIthera Pharmaceuticals
• Gamma Therapeutics
• GlycoMimetics
• Green Cross
• Isis Pharmaceutical
• Leo Pharma
• Pfizer
• Portola Pharmaceuticals
• ThromboGenics
Market driver
• Increasing surgical procedures such as hip and knee replacements.
• For a full, detailed list, view our report
Market challenge
• Presence of alternatives such as thrombectomy and percutaneous techniques.
• For a full, detailed list, view our report
Market trend
• Development of drugs for new indications.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Highlights
PART 05: Disease overview
• Diagnosis of VTE
• Treatment of VTE
PART 06: Pipeline analysis
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by drug class
• Factor Xa inhibitors
• Direct thrombin inhibitors
• Heparin
• Vitamin K antagonists
PART 09: Geographical segmentation
• VTE therapeutics market in Americas
• VTE therapeutics market in EMEA
• VTE therapeutics market in APAC
PART 10: Market drivers
• Increasing adoption of NOACs
• Increasing surgical procedures such as hip and knee replacements
• Large patient pool coupled with growing awareness campaigns
PART 11: Impact of drivers
PART 12: Market challenges
• Presence of alternatives such as thrombectomy and percutaneous techniques
• Unmet needs for anticoagulant reversal agents
• Extensive use of generic products
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Development of drugs for new indications
• Growing focus on emerging economies
• Patient assistance programs
PART 15: Vendor landscape
• Competitive scenario
PART 16: Key vendor analysis
• Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of venous thromboembolism
Exhibit 03: Pipeline analysis
Exhibit 04: Key pipeline molecules
Exhibit 05: Global VTE therapeutics market snapshot
Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global venous thromboembolism market
Exhibit 08: Five forces analysis
Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)
Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions)
Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)
Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021
Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%)
Exhibit 15: Market scenario in Americas
Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: VTE therapeutics market in EMEA ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Forcefield analysis of drivers and challenges
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015
Exhibit 25: Competitive analysis of global VTE therapeutics market 2016
Exhibit 26: Market share analysis 2015
Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016
Exhibit 28: Strategic success factors of companies in global VTE therapeutics market
Exhibit 29: Bayer HealthCare: Key highlights
Exhibit 30: Bayer HealthCare: Strength assessment
Exhibit 31: Bayer HealthCare: Strategy assessment
Exhibit 32: Bayer HealthCare: Opportunity assessment
Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)
Exhibit 34: BMS: Key highlights
Exhibit 35: BMS: Strength assessment
Exhibit 36: BMS: Strategy assessment
Exhibit 37: BMS: Opportunity assessment
Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)
Exhibit 39: Geographic segmentation of Eliquis 2015
Exhibit 40: Boehringer Ingelheim: Key highlights
Exhibit 41: Boehringer Ingelheim: Strength assessment
Exhibit 42: Boehringer Ingelheim: Strategy assessment
Exhibit 43: Boehringer Ingelheim: Opportunity assessment
Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)
Exhibit 45: Daiichi Sankyo: Key highlights
Exhibit 46: Daiichi Sankyo: Strength assessment
Exhibit 47: Daiichi Sankyo: Strategy assessment
Exhibit 48: Daiichi Sankyo: Opportunity assessment
Exhibit 49: Johnson & Johnson: Key highlights
Exhibit 50: Johnson & Johnson: Strength assessment
Exhibit 51: Johnson & Johnson: Strategy assessment
Exhibit 52: Johnson & Johnson: Opportunity assessment
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)
Exhibit 54: Sanofi: Key highlights
Exhibit 55: Sanofi: Strength assessment
Exhibit 56: Sanofi: Strategy assessment
Exhibit 57: Sanofi: Opportunity assessment
Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
Exhibit 59: Geographical segmentation of Lovenox 2015
